News

Labatec Pharma SA (Labatec) has signed an exclusive licensing agreement with Futura Medical plc (AIM: FUM) (Futura), for the rights to commercialise the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment MED3000. Under the terms of the agreement, which is for an initial 8-year period, Futura and Labatec will work together to gain marketing authorisation and […]

Sintra, 30th June 2021 – Labatec inaugurated its first factory in Portugal, in the presence of the Secretary of State for Internationalization, Eurico Brilhante Dias, the Infarmed Vice President, António Faria Vaz, the Swiss Ambassador to Portugal, André Regil and the Mayor of Sintra, Basílio Horta. The project started in January 2018, and three years later, after […]

LABATEC WOMEN HEALTH AND MITHRA ANNOUNCE THE SUCCESSFUL LAUNCH OF MYLOOP® IN SWITZERLAND A hormonal contraceptive ring   Geneva, 10th of June 2021 – LABATEC successfully launches a contraceptive vaginal ring – MyLoop® manufactured by our partner Mithra. About MyLoop® This contraceptive vaginal ring is a generic of NuvaRing®. This medicine will be marketed as MyLoop®, […]

Swissmedic approves Intrarosa® (prasterone) for the treatment of vulvovaginal atrophy in postmenopausal women A novel drug for the treatment of vulvovaginal atrophy based on prasterone (DHEA)   Geneva, the 02.06.2020 – On 19.05.2020, Swissmedic, the Swiss Agency for Therapeutic Products, granted a marketing authorization for the active substance prasterone for the local treatment of vulvovaginal […]